India markets close in 3 hours 45 minutes
  • BSE SENSEX

    52,134.34
    -210.11 (-0.40%)
     
  • Nifty 50

    15,615.25
    -68.10 (-0.43%)
     
  • USD/INR

    74.1530
    +0.0140 (+0.02%)
     
  • Dow

    33,290.08
    -533.32 (-1.58%)
     
  • Nasdaq

    14,030.38
    -131.02 (-0.93%)
     
  • BTC-INR

    2,562,031.50
    -80,227.75 (-3.04%)
     
  • CMC Crypto 200

    858.01
    -81.94 (-8.72%)
     
  • Hang Seng

    28,351.40
    -449.87 (-1.56%)
     
  • Nikkei

    27,965.08
    -999.00 (-3.45%)
     
  • EUR/INR

    88.0324
    +0.0618 (+0.07%)
     
  • GBP/INR

    102.4017
    +0.0457 (+0.04%)
     
  • AED/INR

    20.1420
    +0.0010 (+0.00%)
     
  • INR/JPY

    1.4784
    -0.0050 (-0.34%)
     
  • SGD/INR

    55.1270
    +0.0470 (+0.09%)
     

Shilpa Medicare soars after tie up with Dr. Reddy's for Sputnik V vaccine

·1-min read

In an exchange filing on Monday, Shilpa Medicare said that through its wholly owned subsidiary, Shilpa Biologicals Private Limited, the company has entered into a three-year definitive agreement with Dr. Reddy's Laboratories for production and supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production.

Dr. Reddy's has partnered with HV/RDIF for clinical development of the vaccine and has distribution rights in geographies including India. Dr. Reddy's will facilitate the transfer of the sputnik technology to Shilpa Biologicals. Under the agreement, Shilpa Biologicals will be responsible for manufacture of the vaccine, while DRL is responsible for distribution/marketing of the vaccine in its marketing territories. The companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future.

The company views biologics as a strategic growth area and has made significant investments in setting up a High end, Flexible Biologics facility in Dharwad to cater to the requirements of the fast growing biologics field, that include the adenoviral, subunit & DNA vaccines, Monoclonal antibodies & fusion proteins.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets. The company's consolidated net profit dropped 86% to Rs 7.67 crore on a 19.3% fall in net sales to Rs 191.25 crore in Q3 FY21 over Q3 FY20.

Source: Capitalmarket.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting